Skip Navigation

Rheumatology 2008 47(2):119-120; doi:10.1093/rheumatology/kem294
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wailoo, A.
Right arrow Articles by Chilcott, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wailoo, A.
Right arrow Articles by Chilcott, J.
Related Collections
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIAL

Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

A. Wailoo1, N. Bansback1,2 and J. Chilcott1

1Health Economics and Decision Science, ScHARR, University of Sheffield, UK and 2Centre for Health Evaluation and Outcome Sciences, University of British Columbia, Vancouver, Canada

Correspondence to: A. Wailoo, Health Economics and Decision Science, ScHARR, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK. E-mail: a.j.wailoo@sheffield.ac.uk

The first 150 words of the full text of this article appear below.

Background

Recent editions of this journal have seen papers published that report on the cost-effectiveness of etanercept [1] and adalimumab [2] in AS. These join similar analyses for infliximab [3, 4]. Each of these studies was commissioned by the drug manufacturers (Wyeth, Abbott and Schering Plough, respectively) and are consistent in terms of their conclusions: each of the TNF-{alpha} inhibitors is likely to be cost-effective in the UK National Health Service (NHS) compared with conventional therapy. Readers might therefore expect the National Institute for Health and Clinical Excellence (NICE), which is currently considering the use of these treatments for AS in the NHS and has received cost-effectiveness evidence from all three manufacturers, to issue guidance that recommends the use of these drugs in the NHS. However, the issues that the NICE Technology Appraisals Committee have had to consider are not as straightforward as implied . . . [Full Text of this Article]

General features of the analyses

What happens to BASDAI/BASFI over the long term for patients who remain on therapy?
What happens to BASDAI/BASFI when patients withdraw?

Overview


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
Editor
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: Editor's note
Rheumatology, October 1, 2008; 47(10): 1590 - 1591.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Kobelt
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
Rheumatology, October 1, 2008; 47(10): 1589 - 1590.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Wailoo, N. Bansback, and J. Chilcott
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
Rheumatology, October 1, 2008; 47(10): 1590 - 1590.
[Full Text] [PDF]